Medleaf, New Zealand’s leading Medical Cannabis brand in 2020, is planning to run a Capital Raise in early 2021.

Medleaf is amongst the leading NZ companies, having achieved several milestones.
1st with product for supply
1st applications under new scheme submitted by a New Zealand company.
1st to generate $1 million of revenue
Fully licensed for intended operations.

For the FY 2020 year, Medleaf is on track to generate approximately $1.2million of revenue, and with a Capex nil model, is possibly the safest investment of all Cannabis companies in NZ.

If you would like to keep up with developments and potentially invest, please click here to register your interest and stay up to date.